Neuroendocrine phenotype of non-small cell lung carcinoma: Immunohistological evaluation and biochemical study

International Journal of Biological Markers

Volumn 20, Issue 4, 2005, Pages 217-226

  Slodkowska, Janina ^a   Zych, J ^a   Szturmowics, M ^a   Demkow, U ^a   Rowinska Zakrzewska, E ^a   Roszkowski Sliz, K ^a  

^a NATIONAL TUBERCULOSIS AND LUNG DISEASES RESEARCH INSTITUTE   (Poland)

Author keywords

Chromogranin A; Leu7; Neuroendocrine differentiation; Neuroendocrine tumor markers; Neuron specific enolase; Non small cell lung carcinoma; Serum neuroendocrine biomarkers; Synaptophysin

Indexed keywords

CD57 ANTIGEN; CHROMOGRANIN A; NEURON SPECIFIC ENOLASE; SYNAPTOPHYSIN; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CANCER STAGING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUROSECRETORY CELL; PHENOTYPE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR DIFFERENTIATION;

EID: 30844473530     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460080502000404     Document Type: Article

References (43)

1. Berendsen HH, de Leij L, Poppema S, et al. Clinical characterization of non-small cell lung cancer tumors showing neuroendocrine differentiation features. J Clin Oncol 1989; 7: 1614-20.
2. Graziano SL, Mazid R, Newman N, et al. The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small cell lung cancer. J Clin Oncol 1989; 7: 1398-406.
3. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. Histological typing of lung and pleural tumours. Berlin: Springer Verlag 1999; 31-40.
4. Travis WD, Linnoila RI, Tsokos MG, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol 1991; 15: 529-52.
5. Lyda MH, Weiss LM. Immunoreactivity for epithelial and endocrine antibodies are useful in the differential diagnosis of lung carcinomas. Hum Pathol 2000; 31: 980-7.
6. Linnoila RI, Mulshine JL, Steinberg SM, et al. Neuroendocrine differentiation in endocrine and nonendocrine lung carcinomas. Am J Clin Pathol 1988; 90: 641-52.
7. Pelosi G, Pasini F, Sonzogni A, et al. Prognostic implications of neuroendocrine differentiation and hormone production in patients with stage I non-small cell lung carcinoma. Cancer 2003; 97: 2487-97.
8. Skov BG, Sorensen JB, Hirsch FR, Larsson LI, Hansen HH. Prognostic impact of histologic demonstration of chromogranin A and neuron specific enolase in pulmonary adenocarcinoma. Ann Oncol 1991; 2: 355-60.
9. Carles J, Rosell R, Ariza A, et al. Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer. Lung Cancer 1993; 10: 209-19.
10. Schleusener JT, Tazelaar HD, Jung SH, et al. Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated non-small cell lung carcinoma. Cancer 1996; 77: 1284-91.
11. Linnoila RI, Piantadosi S, Ruckdeschel JC. Impact of neuroendocrine differentiation in non-small cell lung carcinoma. The LCSG experience. Chest 1994; 106 (Suppl 6): 367s-71s.
12. Sundaresan V, Reeve JG, Stenning S, Stewart S, Bleehen N. Neuroendocrine differentiation and clinical behaviour in non-small cell lung tumours. Br J Cancer 1991; 64: 333-8.
13. Graziano SL, Tatum AH, Newmann NB, et al. The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected stage I and stage II non-small cell lung cancer. Cancer Res 1994; 54: 2908-13.
14. Graziano SL, Tatum A, Herndon JE, et al. Use of neuroendocrine markers, p53 and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study. Lung Cancer 2001; 333: 115-23.
15. Brambilla E, Veale D, Moro D, Brambilla C. Neuroendocrine phenotype in lung cancers. Comparison of immunohistochemistry with biochemical determination of enolase isoenzymes. Am J Clin Pathol, 1992; 98: 88-97.
16. Hiroshima K, Iyoda A, Shibuya K, et al. Prognostic significance of neuroendocrine differentiation in adenocarcinoma of the lung. Ann Thorac Surg 2002; 73: 1732-5.
17. Lamy P, Grenier J, Kramar A, Pujol JL. Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer. Lung Cancer 2000; 29: 197-200.
18. Johnson PW, Joel SP, Love S, et al. Tumor markers for prediction of survival and monitoring of remission in small cell lung cancer. Br J Cancer 1993; 67: 760-7.
19. Burghuber OC, Worofka B, Schernthaner G, et al. Serum neuron-specific enolase is a useful tumor marker for small cell lung cancer. Cancer 1990; 65: 1386-90.
20. Pujol JL, Boher JM, Grenier J, Quantin X. Cyfra 21-1, neuron specific enolase and prognosis of non-small cell cancer: prospective study in 621 patients. Lung Cancer 2001; 31: 221-31.
21. Van Zandwijk N, Jassem E, Bonfrer JMG, Mooi WJ, Van Tinteren H. Serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy and survival in non-small cell lung cancer. Semin Oncol 1992; 19: 37-43.
22. Ferrigo D, Buccheri G, Giordano C. Neuron-specific enolase is an effective tumour marker in non-small cell lung cancer (NSCLC). Lung Cancer 2003; 41: 311-20.
23. Zych J, Szturmowicz M, Sakowicz A, et al. Wartosc stezenia neuronoswoistej enolazy (NSE) w surowicy chorych na niedrobnokomorkowego raka pluca w prognozowaniu wynikow leczenia cytostatycznego. Pneumonol Alergol Pol 2002; 70: 278-83.
24. O'Shea P, Cassidy M, Freaney R, McCarthy P, Fennelly J. Serum neuron-specific enolase and immunohistochemical markers of neuroendocrine differentiation in lung cancer. Ir J Med Sci 1995; 164: 31-6.
25. Sobin LH, Wittekind C. International Union Against Cancer: Lung and pleural tumours. In: TNM Classification of Malignant Tumors, 5th ed. New York: Wiley, 1997.
26. Pujol JL, Simony J, Demoly P, et al. Neuronal cell adhesion molecule and prognosis of surgically resected lung cancer. Am Rev Respir Dis 1993; 148: 1071-5.
27. Iyoda A, Hiroshima K, Toyozaki T, et al. Clinical characterisation of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology. Cancer 2001; 91: 1992-2000.
28. von Rohr A, Hasleton PS, Quigley A, Thatcher N. Expression of neuroendocrine markers in non-small cell lung cancer. Proc Eur Soc Med Oncol 1992; 108.
29. Wallace WA. Focal neuroendocrine differentiation in non-small cell carcinoma is not predicted by pre-operative routine investigation. Eur J Surg Oncol 2002; 28: 63-6.
30. Gazdar AF, Helman LJ, Israel MA, et al. Expression of neuroendocrine cell markers L-dopa decarboxylase, chromogranin A and dense core granules in human tumors of endocrine and nonendocrine origin. Cancer Res 1988; 48: 4078-82.
31. Dranoff G, Bigner DD. A word of caution in the use of neuron-specific enolase expression in tumor diagnosis. Arch Pathol Lab Med 1984; 108: 535.
32. Leader M, Collins M, Patel J, Henry K. Antineuron specific enolase staining reactions in sarcomas and carcinomas; Its lack of neuroendocrine specificity. J Clin Pathol 1986; 39: 1186-92.
33. Satoh H, Ishikawa H, Kurishima K, Yamashita YT, Ohtsuka M, Sekizawa K. Cut-off levels of NSE to differentiate SCLC from NSCLC. Oncology Rep 2002; 9: 581-3.
34. Ariyoshi Y, Kato K, Ishiguro Y, Ota K, Sato T, Suchi T. Evaluation of serum neuron-specific enolase as a tumor marker for carcinoma of the lung. Gann 1983; 74: 219-25.
35. Szturmowicz M, Burakowski J, Tomkowski W, Sakowicz A, Filipecki S. Neuron specific enolase in non-neoplastic lung diseases, a marker of hypoxemia? Int J Biol Markers 1998; 13: 150-3.
36. Manna A, Reale MG, Marchei GG, et al. NSE (neuron specific enolase): Pulmonary pathologies and diabetic neuropathy. XIX ISOBM Meeting, Siena, Italy, 13-17 October 1991; 324.
37. Barone FC, Clarck RK, Price WJ, et al. Neuron-specific enolase increases in cerebral and systemic circulation following focal ischemia. Brain Res 1993; 623: 77-82.
38. Stivanello M, Berruti A, Torta M, et al. Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience. Ann Oncol 2001; 12 (Suppl 2): S73-7.
39. Nobels FR, Kwekkeboom DJ, Coopmans W, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 1997; 82: 2622-8.
40. Seregni E, Ferrari L, Bajetta E, Martinetti A, Bombardieri E. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann Oncol 2001;12 (Suppl 2): S69-S72.
41. Sobol RE, O'Connor DT, Addison J, et al. Elevated serum chromogranin A concentration in small cell lung carcinoma. Ann Intern Med 1986; 105: 698-70.
42. Ferrari L, Seregni E, Martinetti A, et al. Chromogranin A measurement in neuroendocrine tumors. Int J Biol Markers 1998; 13: 3-9.
43. Hage R, Elbers HR, Brutel de la Riviere A, van den Bosch JMM. Neural cell adhesion molecule expression: prognosis in 889 patients with resected non-small cell lung cancer. Chest 1998; 114: 1316-20.